Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/200528ISOLATED PRIMARY DERMAL FIBROBLASTS FOR TREATING SKIN CONDITIONS
WO 29.09.2022
Int.Class A61K 35/33
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
33Fibroblasts
Appl.No PCT/EP2022/057831 Applicant KING'S COLLEGE LONDON Inventor WATT, Fiona
Provided herein is method of treating a skin condition in a subject, comprising isolating cells comprising primary dermal fibroblasts from a skin sample obtained from the subject, and administering the freshly-isolated cells to skin of the subject. Also provided are freshly isolated cell preparations comprising primary dermal fibroblasts and uses thereof.
2.WO/2022/203303LACTOBACILLUS PLANTARUM GB104 STRAIN AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CANCER
WO 29.09.2022
Int.Class A61K 35/747
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
747Lactobacilli, e.g. L. acidophilus or L. brevis
Appl.No PCT/KR2022/003890 Applicant GI BIOME Inventor JANG, Myung Ho
The present invention relates to a Lactobacillus Plantarum GB104 strain (accession number: KCTC 14107BP) and a composition comprising same as active ingredient for prevention or treatment of cancer. The Lactobacillus plantarum GB104 strain according to the present invention increases production of INF-γ and granzyme B and activates immune cells such as cytotoxic T cells and NK cells, thereby being able to ultimately inhibit the formation and growth of tumors. Therefore, a composition comprising the Lactobacillus plantarum GB104 strain of the present invention as an active ingredient increases immune activity in the body and thus can be effectively utilized for treatment of cancer diseases and is highly industrially applicable.
3.20220306978CELL CAPTURE AND EXPANSION
US 29.09.2022
Int.Class C12M 1/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
12with sterilisation, filtration, or dialysis means
Appl.No 17702658 Applicant Terumo BCT, Inc. Inventor Mark E. Jones

Implementations are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In implementations, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other implementations, the cells may be grown in co-culture with other cells, e.g., hMSC's. In implementations, the cells may include CD34+ cells. A coated membrane includes a membrane having a first coating configured to promote cellular adhesion to the membrane and a second coating that includes a soluble protein moiety.

4.WO/2022/204474CAR-T DELIVERY OF SYNTHETIC PEPTIDE THERAPEUTICS
WO 29.09.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2022/021877 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor JOHNSON, Lexus R.
The present disclosure provides engineered cells (e.g., T cells) comprising a chimeric antigen receptor (CAR) and a therapeutic peptide, and methods of use thereof.
5.WO/2022/204129CD38 CHIMERIC CO-STIMULATING RECEPTOR AND USES THEREOF
WO 29.09.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/US2022/021325 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor SADELAIN, Michel
The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.
6.WO/2022/204564METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
WO 29.09.2022
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No PCT/US2022/022030 Applicant IOVANCE BIOTHERAPEUTICS, INC. Inventor SIMPSON-ABELSON, Michelle, R.
The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
7.WO/2022/204714ZINC-BASED PHYSIONANOCOMPOSITES AND METHODS OF USE THEREOF
WO 29.09.2022
Int.Class A01N 59/16
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
59Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
16Heavy metals; Compounds thereof
Appl.No PCT/US2022/071334 Applicant KANSAS STATE UNIVERSITY RESEARCH FOUNDATION Inventor DELONG, Robert
The present disclosure provides ZnS-based compositions that treat cancer and viral infections. The ZnS compositions can further include manganese or iron and/or be doped with manganese (Mn), iron (Fe), nickel (Ni), cobalt Co), cobalt ferrite (CoFe), and any combination thereof.
8.20220305058MESENCHYMAL STROMAL CELL BONE GRAFT MATERIAL
US 29.09.2022
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
Appl.No 17635664 Applicant Johann Wolfgang Goethe-Universität Frankfurt am Main Inventor Dirk HENRICH

The invention pertains to the use of mesenchymal stromal cells (MSC) in the treatment of bone disorders or injuries. The invention provides MSC and preparations of specifically pooled MSC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis. The invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.

9.WO/2022/201035VACCINES AND IMMUNOGLOBULINS TARGETING AFRICAN SWINE FEVER VIRUS, METHODS OF PREPARING SAME, AND METHODS OF USING SAME
WO 29.09.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/IB2022/052621 Applicant IGY IMMUNE TECHNOLOGIES AND LIFE SCIENCES INC. Inventor NGUYEN, Huan Huu
The present disclosure provides a method of isolating and preparing live African Swine Fever (ASF) viruses (ASFV) and an ASFV vaccine composed of ASF virus particles, ASF viral components, and/or immunosuppressive protein factors. The ASFV vaccine can be used to immunize pigs and wild boars, or can be used to immunize species other than pig or wild boar, such as fowl, bovine, goat, rabbit, donkey or horse, to generate polyclonal immunoglobulins with broad-spectrum specificity to the ASFV. The ASFV-specific immunoglobulins then can be extracted and purified. The ASFV-specific immunoglobulins can provide acute treatment of ASF-infected pigs or wild boars or preventative treatment for pigs or wild boars at risk of ASF, for example that may have been exposed to ASFV or ASFV-infected subjects.
10.20220305141SKELETAL MYOBLAST PROGENITOR CELL LINEAGE SPECIFICATION BY CRISPR/CAS9-BASED TRANSCRIPTIONAL ACTIVATORS
US 29.09.2022
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17636754 Applicant Duke University Inventor Charles A. Gersbach

Disclosed herein are methods and systems for increasing expression of Pax7, methods of activating endogenous myogenic transcription factor Pax7 in a cell, methods of differentiating a stem cell into a skeletal muscle progenitor cell, as well as compositions and methods for treating a subject in need of regenerative muscle progenitor cells. The compositions and methods may include a Cas9-based transcriptional activator protein and at least one guide RNA (gRNA) targeting Pax7.